On Tuesday, Quebec decided to lower its minimum age requirement for the AstraZeneca vaccine from 55 to 45 years.
This came days after British Columbia, Manitoba, Alberta and Ontario decided to open AstraZeneca COVID-19 vaccine bookings to those aged 40 and older, down from the previous age requirement of 55 years and older.
The change goes against the country’s National Advisory Committee on Immunization (NACI) recommendation to not give the vaccine to those under the age of 55 because of concerns over reports of rare blood clots.
Canada’s federal health minister, Patty Hajdu, has said that provinces and territories were “free to use” AstraZeneca’s vaccine on any groups aged 18 and above, despite the NACI guidelines.
But some experts fear the discrepancies could fuel vaccine hesitancy and confuse average Canadians.
“It contributes to vaccine hesitancy significantly,” Kerry Bowman, a bioethicist at the University of Toronto, said.
“Different provinces drawing the line in different places suggest these are not scientifically grounded decisions at all, further eroding public trust.”
On Wednesday, long lines were seen at several vaccination sites in Montreal as people queued up to get the AstraZeneca shot a day after the provincial government expanded access.
Quebec decided to make the switch based on a risk-benefit analysis conducted by its national immunization committee.
In its report released on Tuesday, the committee found that for all age groups in the province, the benefits of the Oxford-AstraZeneca vaccine outweigh the risks, but it said the benefits for people over 45 are far higher than for younger people.
The committee weighed the number of hospitalizations prevented for every 100,000 people given the AstraZeneca vaccine with the expected number of patients who would get blood clots.
It found that the number of hospitalizations prevented would be higher for all adults. But the number of intensive care unit (ICU) admissions prevented would only be significantly higher for people over 45.
“Starting at 45 years of age, there’s really a high number of people hospitalized and going to intensive care due to COVID-19,” Nicholas Brousseau, chair of Quebec’s immunization committee, told Global News Wednesday.
“So that’s why to get the AstraZeneca vaccine earlier is a good idea for those 45 years of age and older, because really the benefits seem to clearly outweigh the potential risk of side effects,” he said.
However, Quebec’s age requirement for the AstraZeneca shot differs from other provinces. Experts say the daily COVID-19 case counts are largely responsible for that.
The province also has a lower proportion of cases involving variants of concern (VOC) compared to Alberta, Ontario and B.C.
“There are more far more cases in the west of Canada [and] in Ontario at the moment, so that’s why it’s normal, I think, that they chose a lower age limit,” said Brousseau.
As of Wednesday, Quebec had 340,397 coronavirus cases, while Ontario’s total case count stood at 429,123 and B.C’s at 120,889.
Christopher Labos, an epidemiologist and cardiologist based in Montreal, said because the situation in Quebec is “relatively more stable, there is not this push to get as many people vaccinated as quickly as possible.”
The COVID-19 crisis in Ontario — which is ravaged by the third wave — is growing increasingly dire.
Meanwhile, Alberta is also facing an upward trajectory of cases and hospital admissions.
Labos said there was “no right or wrong or answer” when it comes to the vaccine rollout strategy.
He said the 55-year cutoff that was originally chosen by NACI was to “a certain degree, somewhat arbitrary.”
“Some people picked the 10-year increments; some people picked the 15-year increment. There’s no real science behind it per se,” Labos told Global News.
“But the fundamental rationale for it remains fairly consistent, which is even relatively younger people will still benefit from getting vaccinated because the risk associated with COVID is so much more imminent and dangerous in the short term.”
© 2021 Global News, a division of Corus Entertainment Inc.